Patient Affairs, Medical Affairs, Patient-centric R&D
Roz Schneider is a visionary in human-centered design in biopharmaceutical research and healthcare, with experience spanning clinical practice, academia, and hospital administration in Internal Medicine, Pulmonary, and Critical Care medicine, as well as significant industry leadership. A mentor and advocate for gender equity, she has held leadership roles in professional associations and has received numerous accolades, including the Global Fellowship in Medicines Development and recognition from the CUNY School of Medicine
Expertise
- Served as Vice President of Global Patient Affairs, BioMarin where under her leadership, BioMarin’s 2023 Rare Disease corporate reputation rose to #2 from #10 ranked by patient groups familiar with them.
- Created a new global function and led Global Patient Affairs at Pfizer where she advanced patient-centered design that became a model for the industry. Her work there was recognized by FDA, EMA, and PMDA by whom she was invited to share insights. In her Medical Affairs roles, she led a Competitive Medical Strategy Team supporting the launch of Eliquis, with $12.2B annual revenue in 2023 and total revenue exceeding $69B since 2012 launch.
- Serves as an active member of Women Execs on Boards, the Exceptional Women Alliance, board chair for the American Lung Association’s New Jersey Chapter, and is a board member of the Global Medicine Development Program Academy, King’s College of London, and Strategic Advisory Board Member of ProofPilot
Experience
- Excels at leading commercial and cross-functional teams, and launching and marketing new products in U.S. and international markets.
- Enabling more robust decision-making in medical product development, accelerating clinical trial enrollment, and reducing clinical study amendments, saving millions in development operations costs.
- Optimizing patient centricity and ensuring patients engagement in drug development